Level Four Advisory Services LLC Sells 1,625 Shares of Edwards Lifesciences Co. (NYSE:EW)

Level Four Advisory Services LLC lessened its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 29.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,825 shares of the medical research company’s stock after selling 1,625 shares during the period. Level Four Advisory Services LLC’s holdings in Edwards Lifesciences were worth $283,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in Edwards Lifesciences by 86.3% in the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Norges Bank bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $610,895,000. Jennison Associates LLC acquired a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $555,939,000. Vanguard Group Inc. increased its position in Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock worth $5,117,845,000 after acquiring an additional 6,537,494 shares during the period. Finally, Assenagon Asset Management S.A. raised its stake in Edwards Lifesciences by 475.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after purchasing an additional 3,506,886 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 1.0 %

NYSE:EW opened at $71.77 on Wednesday. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market cap of $42.19 billion, a PE ratio of 10.30, a P/E/G ratio of 4.82 and a beta of 1.12. The firm’s 50 day simple moving average is $71.59 and its 200 day simple moving average is $70.59.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. On average, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total value of $797,287.50. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at approximately $2,153,526.69. This trade represents a 27.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 62,553 shares of company stock valued at $4,513,064 over the last ninety days. 1.29% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Barclays raised their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Morgan Stanley raised their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Truist Financial reiterated a “hold” rating and set a $78.00 target price (up from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler upped their price objective on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.